Literature DB >> 2146135

Detection of autoantibodies to Sm antigen in systemic lupus erythematosus by immunodiffusion, ELISA and immunoblotting: variability of incidence related to assays and ethnic origin of patients.

N Abuaf1, C Johanet, P Chretien, B I Absalon, J C Homberg, J F Buri.   

Abstract

Autoantibodies to small nuclear ribonucleoproteins (snRNP) were studied using the techniques of immunodiffusion, ELISA, and immunoblotting in the sera of 150 patients with systemic lupus erythematosus (SLE), and of 29 patients with mixed connective tissue disease; 900 control patients and 100 normal blood donors were examined simultaneously. The incidence of anti-Sm antibodies in French SLE patients was low compared with the occurrence observed in similar studies in USA (even when highly sensitive assays were used) but was of the same magnitude as European results. Frequency of anti-Sm antibodies in SLE patients varied moderately when detected by immunodiffusion (12%), or by immunoblotting (17%), however, it seems that the ethnic and/or genetic background of patients induces more significant differences. SLE patients from the French West Indies had anti-Sm antibodies in 39% of cases when detected by immunodiffusion and in 50% when immunoblotting was used. In these patients the incidence of the antibodies was five times more frequent than that of mainland French patients. Immunization against snRNP does not seem to be a common feature of all SLE patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146135     DOI: 10.1111/j.1365-2362.1990.tb01870.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  9 in total

1.  Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations.

Authors:  M Tikly; S Burgin; P Mohanlal; A Bellingan; J George
Journal:  Clin Rheumatol       Date:  1996-05       Impact factor: 2.980

2.  Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations.

Authors:  M Tikly; S Burgin; P Mohanlal; A Bellingan; J George
Journal:  Clin Rheumatol       Date:  1996-03       Impact factor: 2.980

3.  Mapping of epitopes on U1 snRNP polypeptide A with synthetic peptides and autoimmune sera.

Authors:  S Barakat; J P Briand; N Abuaf; M H van Regenmortel; S Muller
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

4.  Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay.

Authors:  M Mahler; L M Stinton; M J Fritzler
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

5.  A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus.

Authors:  G Riemekasten; J Marell; G Trebeljahr; R Klein; G Hausdorf; T Häupl; J Schneider-Mergener; G R Burmester; F Hiepe
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

6.  Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies.

Authors:  Michael Mahler; Marvin J Fritzler; Martin Blüthner
Journal:  Arthritis Res Ther       Date:  2004-11-10       Impact factor: 5.156

7.  Evaluating Anti-SmD1-amino-acid 83-119 Peptide Reactivity in Children with Systemic Lupus Erythematosus and Other Immunological Diseases.

Authors:  Hai-Ou Yang; Xiao-Qing Zhang; Qi-Hua Fu
Journal:  Chin Med J (Engl)       Date:  2016-12-05       Impact factor: 2.628

8.  Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus.

Authors:  Michael Mahler; Aderajew Waka; F Hiepe; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 9.  Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology.

Authors:  Mandy Sowa; Rico Hiemann; Peter Schierack; Dirk Reinhold; Karsten Conrad; Dirk Roggenbuck
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.